I think CRIS at $250 million "might" be undervalued considering they are first-in-class with Hedgehog (even though they get very small royalties in a small indication); but, there's more to the story there.
IMUC, might be. ARRY, might be. ONTY, might be.
Basically, it comes down to this: there are a lot of biotechs out there trading at $1.5-$2 billion market caps. If the market continues to speculate, the small cap companies with market caps of less than $300 million are going to "catch up" (I believe) going into ASCO. IMO, biotechs could get a little crazy if the market continues to go North.
Ride the wave. Just know when to hop off onto shore. Will I? I don't know....I hope so.
